New Larger Vial Sizes Will Be Available Beginning in July 2025 to Help Streamline the GLASSIA Infusion Experience

GLASSIA Is the Only Ready-to-Use Liquid Treatment for Appropriate Patients with Alpha-1 Antitrypsin Deficiency Approved for Self-Administration after Receiving Training¹

**CAMBRIDGE, Massachusetts, March 11, 2025** – Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has approved an update to the GLASSIA^® (Alpha-1 Proteinase Inhibitor [Human]) U.S. Prescribing Information, which now includes 1-, 4- and 5-gram single-dose vial sizes. The 1-gram vial size of GLASSIA was originally approved in 2010. The new larger vial sizes will be available beginning July 2025 to help streamline the GLASSIA infusion experience for patients who previously needed four or more 1-gram vials per infusion, due to its weight-based dosing instructions. The availability of larger vial sizes also has the potential to reduce waste and maximize storage efficiencies for customers and for patients who self-infuse. With four infusion setting options, GLASSIA is the only ready-to-use liquid treatment for appropriate patients with alpha-1 antitrypsin deficiency (alpha-1) approved for self-administration after receiving training.¹

“The availability of GLASSIA in 4- and 5-gram vials demonstrates our continued commitment to improving the treatment experience for the alpha-1 community.” said Rick Ascroft, senior vice president and head of the U.S. Plasma-Derived Therapies Business Unit. “For patients who self-infuse at home, with proper training, this has the potential to reduce steps in the preparation and administration process, requiring fewer vials and supplies for infusions.”

At least 100,000 people in the U.S. have alpha-1, and more than 90% don’t know they have it.^2,3,4,5 People with severe hereditary alpha-1 have low or absent serum levels of the protective protein in their blood and lungs, which places them at risk for early-onset chronic obstructive pulmonary disease (COPD), emphysema or liver disease.^6,7 Alpha-1 is a genetic (inherited) condition, which means it runs in families.⁶

About GLASSIA

GLASSIA is an Alpha₁-Proteinase Inhibitor (Human) (Alpha₁-PI) indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha₁-PI (alpha₁-antitrypsin deficiency).

The effect of augmentation therapy with GLASSIA or any Alpha₁-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha₁-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with GLASSIA are not available. GLASSIA is not indicated as therapy for lung disease in patients in whom severe Alpha₁-PI deficiency has not been established.

IMPORTANT SAFETY INFORMATION

Contraindications

Immunoglobulin A (IgA) deficient patients with antibodies against IgA
History of anaphylaxis or other severe systemic reaction to Alpha₁-PI products.

Warnings and Precautions

Hypersensitivity: GLASSIA may contain trace amounts of IgA. Monitor vital signs continuously and observe the patient throughout the infusion. If hypersensitivity symptoms occur, discontinue the infusion and administer appropriate emergency treatment. Have epinephrine and/or other appropriate supportive therapy available for any acute anaphylactic or anaphylactoid reaction.

Transmissible Infectious Agents: Because GLASSIA is made from human plasma it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent and other pathogens. No seroconversions for hepatitis B or C or human immunodeficiency virus or any other known infectious agent were reported with the use of GLASSIA during the clinical trials.

Adverse Reactions

The serious adverse reaction observed during clinical trials with GLASSIA was exacerbation of chronic obstructive pulmonary disease (COPD).

The most common adverse reactions during clinical trials were headache and upper respiratory infection.

Please click for GLASSIA Full Prescribing Information.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit v8.t66039.com.

Media Contacts:

U.S. Media

Taryn Corbino

Taryn.Corbino@t66039.com

Takeda Media Relations

media_relations@t66039.com

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: http://v8.t66039.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

GLASSIA^® (Alpha-1 Proteinase Inhibitor [Human]) U.S. Prescribing Information.
Torres-Durán et al. Orphanet J Rare Dis. 2018;13(1):114.
Nakanishi T, Forgetta V, Handa T, et al. Eur Respir J. 2020;56(6):2001441.
Stoller JK, Aboussouan LS. Am J Respir Crit Care Med. 2012 Feb 1;185(3):246-59.
Horváth I, Cançado J, Luisetti M, et al. ERJ Open Res. 2019;5(1):00171-2018.
Brode SK, Ling SC, Chapman KR. Canadian Medical Association Journal. 2012;184(12):1365-1371.
Kueppers F, Sanders C. Allergy Asthma Proc. 2017;38(2):108-114.